Cargando…

The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response

Escape mutations in the spike protein of SARS-CoV-2 are a major reason for Omicron breakthrough infections. After basal vaccination only very low titers of Omicron neutralizing antibodies are present. However, booster vaccinations induce higher titers against the Omicron variant. The neutralization...

Descripción completa

Detalles Bibliográficos
Autores principales: Hein, Sascha, Sabino, Catarina, Benz, Nuka Ivalu, Görgülü, Esra, Maier, Thorsten Jürgen, Oberle, Doris, Hildt, Eberhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319856/
https://www.ncbi.nlm.nih.gov/pubmed/37402816
http://dx.doi.org/10.1038/s41598-023-38077-x
_version_ 1785068328328364032
author Hein, Sascha
Sabino, Catarina
Benz, Nuka Ivalu
Görgülü, Esra
Maier, Thorsten Jürgen
Oberle, Doris
Hildt, Eberhard
author_facet Hein, Sascha
Sabino, Catarina
Benz, Nuka Ivalu
Görgülü, Esra
Maier, Thorsten Jürgen
Oberle, Doris
Hildt, Eberhard
author_sort Hein, Sascha
collection PubMed
description Escape mutations in the spike protein of SARS-CoV-2 are a major reason for Omicron breakthrough infections. After basal vaccination only very low titers of Omicron neutralizing antibodies are present. However, booster vaccinations induce higher titers against the Omicron variant. The neutralization of the Delta and Omicron variants by sera obtained 6 months after 3rd vaccination and 2 weeks or 6 months after 4th vaccination with a monovalent RNA vaccine (Spikevax) was analyzed. It was observed for the Omicron variant that 6 months after the fourth vaccination, the titer returns to the same very low neutralizing capacity as 6 months after the third vaccination. The Delta variant neutralizing capacity wanes with a comparable kinetic although the titers are higher as compared to the Omicron variant. This indicates that the fourth vaccination with a monovalent vaccine based on the ancestral isolate neither affects the kinetic of the waning nor the breadth of the humoral response.
format Online
Article
Text
id pubmed-10319856
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103198562023-07-06 The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response Hein, Sascha Sabino, Catarina Benz, Nuka Ivalu Görgülü, Esra Maier, Thorsten Jürgen Oberle, Doris Hildt, Eberhard Sci Rep Article Escape mutations in the spike protein of SARS-CoV-2 are a major reason for Omicron breakthrough infections. After basal vaccination only very low titers of Omicron neutralizing antibodies are present. However, booster vaccinations induce higher titers against the Omicron variant. The neutralization of the Delta and Omicron variants by sera obtained 6 months after 3rd vaccination and 2 weeks or 6 months after 4th vaccination with a monovalent RNA vaccine (Spikevax) was analyzed. It was observed for the Omicron variant that 6 months after the fourth vaccination, the titer returns to the same very low neutralizing capacity as 6 months after the third vaccination. The Delta variant neutralizing capacity wanes with a comparable kinetic although the titers are higher as compared to the Omicron variant. This indicates that the fourth vaccination with a monovalent vaccine based on the ancestral isolate neither affects the kinetic of the waning nor the breadth of the humoral response. Nature Publishing Group UK 2023-07-04 /pmc/articles/PMC10319856/ /pubmed/37402816 http://dx.doi.org/10.1038/s41598-023-38077-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hein, Sascha
Sabino, Catarina
Benz, Nuka Ivalu
Görgülü, Esra
Maier, Thorsten Jürgen
Oberle, Doris
Hildt, Eberhard
The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
title The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
title_full The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
title_fullStr The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
title_full_unstemmed The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
title_short The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
title_sort fourth vaccination with a non-sars-cov-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319856/
https://www.ncbi.nlm.nih.gov/pubmed/37402816
http://dx.doi.org/10.1038/s41598-023-38077-x
work_keys_str_mv AT heinsascha thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT sabinocatarina thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT benznukaivalu thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT gorguluesra thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT maierthorstenjurgen thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT oberledoris thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT hildteberhard thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT heinsascha fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT sabinocatarina fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT benznukaivalu fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT gorguluesra fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT maierthorstenjurgen fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT oberledoris fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse
AT hildteberhard fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse